Skip to main content
SpringerLink
Log in

Pharmacokinetics of ketanserin in patients with essential hypertension

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of ketanserin and its main metabolite ketanserin-ol, and the antihypertensive effects of intravenous, single oral and chronic oral (40 mg once daily) administration of ketanserin, have been investigated in a single blind study of 10 patients with uncomplicated mild hypertension. Ketanserin had a terminal half-life of 29.2 h, a plasma clearance of 518 ml/min and a volume of distribution of 18.0 l/kg. Chronic oral intake of 40 mg ketanserin (tablet formulation) gave a peak concentration of unchanged ketanserin of 88 ng/ml after 1.1 h. Its absolute bioavailability was 48%.

During chronic therapy the maximal concentration of ketanserin-ol was 208 ng/ml and its half-life of elimination was 35.0 h. As this metabolite can be oxidized back to ketanserin, it contributes to the prolonged half-life of unchanged ketanserin seen during chronic therapy.

The blood pressure was reduced by approximately 15% by oral ketanserin. The maximal reduction in blood pressure coincided with the peak concentration of unchanged ketanserin. During chronic therapy with 40 mg once daily blood pressure was reduced over 24 h. The heart rate was slightly reduced and the cardiovascular responses and the plasma noradrenaline concentrations during isometric exercise were only slightly influenced by ketanserin therapy.

Thus, unchanged ketanserin has a relatively long half-life during chronic oral therapy and its pharmacokinetics in middle-aged hypertensive patients is similar to that in normal young volunteers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Janssen PAJ (1985) Pharmacology of potent and selective S2-serotoninergic antagonists. J Cardiovasc Pharmacol 7 [Suppl 7]: S2-S11

    Google Scholar 

  2. Van Nueten J, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren T, Vanhoutte P (1981) Vascular effects of ketanserin (R 41 468), a novel antagonist of 5HT2-serotoninergic receptors. J Pharmacol Exp Ther 218: 217–230

    Google Scholar 

  3. Van Nueten JM, Vanhoutte PM (1984) Cardiovascular pharmacology of ketanserin. In: 3rd Internat Symp Mechanisms of Vasodilatation. Bioltheca Cardiol no 38. Karger, Basle, pp 222–233

    Google Scholar 

  4. Wenting GJ, Woittiez AJJ, Man in't Veld AJ, Schalekamp MADH (1984) 5-HT, alpha-adrenoceptors and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6: 100–109

    Google Scholar 

  5. De Clerck F, David JL, Janssen PAJ (1982) Inhibition of 5-hydroxytrypamine-induced and amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions 12: 388–397

    Google Scholar 

  6. De Clerck F, Xhonneux B, Leysen J, Janssen PAJ (1984) Evidence for functional 5-HT2-receptor sites on human blood platelets. Biochem Pharmacol 33: 2807–2811

    Google Scholar 

  7. DeCree J, Leempoels J, Demoen B, Roels V, Verhaegen H (1985) Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases. J Cardiovasc Pharmacol 7 [Suppl 7]: S26-S28

    Google Scholar 

  8. DeCree J, Verhaegen H, Symoens J (1981) Acute blood-pressure-lowering effect of ketanserin. Lancet 1: 1161–1162

    Google Scholar 

  9. Wenting GJ, Man In't Veld AJ, Woittiez AJ, Boomsma F, Schaelekamp MADH (1982) Treatment of hypertension with ketanserin, a new selective 5-HT2-receptor antagonist. Br Med J 284: 537–539

    Google Scholar 

  10. Persson B, Hedner T, Berglund G (1983) Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Pharmacol 25: 307–312

    Google Scholar 

  11. Hedner T, Persson B, Berglund G (1983) Ketanserin, a novel 5-hydroxytryptamine antagonist: Monotherapy in essential hypertension. Br J Clin Pharmacol 16: 121–125

    Google Scholar 

  12. Hedner T, Persson B, Berglund G (1985) A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. J Cardiovasc Pharmacol 7 [Suppl 7]: S148-S153

    Google Scholar 

  13. Wing LMH, Chalmers JP, West MJ, Bane AJ, Ayres B, Graham JR (1984) The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension. Clin Exp Hypertens A6: 1107–1117

    Google Scholar 

  14. Hedner T, Persson B (1984) Ketanserin in combination with β-adrenergic blocking agents in the treatment of essential hypertension. Br J Clin Pharmacol 18: 765–771

    Google Scholar 

  15. Reimann IW, Okonkwo PO, Klotz U (1983) Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol 25: 73–76

    Google Scholar 

  16. Heykants J, van Peer A, Woestenborghs R, Gould S, Mills J (1986) Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 31: 343–350

    Google Scholar 

  17. Kurowski M (1985) Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol 28: 411–417

    Google Scholar 

  18. Nyberg G (1977) Indirect blood pressure and heart rate measured quickly without observer bias using a semiautomatic machine (Auto-Manometer) — response to isometric exercise in normally healthy males and its modification by β-adrenoceptor blockade. Br J Clin Pharmacol 4: 275–281

    Google Scholar 

  19. Hjemdahl P, Daleskog M, Kahan T (1979) Determination of plasma catecholamines by high performance liquid chromatography with electrochemical determination. Life Sci 25: 131–138

    Google Scholar 

  20. Okonkwo PO, Reimann IW, Woestenborghs R, Klotz U (1983) High performance liquid chromatographic assay, with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2-antagonist in human plasma, blood and urine. J Chromatogr 272: 411–416

    Google Scholar 

  21. Sheiner LB, Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures: Superiority of extended least squares. J Pharmacokinet Biopharm 13: 185–201

    Google Scholar 

  22. Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York

    Google Scholar 

  23. Genest J, Koiw E, Kuchel O (1977) Hypertension. Physiopathology and treatment. McGraw-Hill, New York

    Google Scholar 

  24. Frenken M, Kaumann A (1984) Interaction of ketanserin and its metabolite ketanserin-ol with 5HT2-receptors in pulmonary and coronary arteries of calf. Naunyn Schmiedebergs Arch Pharmacol 326: 334–339

    Google Scholar 

  25. Van Peer A, Woestenborghs R, Embrecht L, Heykants J (1986) Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol 31: 339–342

    Google Scholar 

  26. Hedner T, Pettersson A, Gradin K, Persson B (1986) Peripheral serotoninergic mechanisms in cardiovascular regulation in the SHR. J Hypertens 4 [Suppl 3]: 223–225

    Google Scholar 

  27. DeCree J, Hoing M, de Ryck M, Symoens J (1985) The acute antihypertensive effect of ketanserin increases with age. J Cardiovasc Pharmacol 7 [Suppl 7]: S126-S127

    Google Scholar 

  28. Symoens J, Vanhoutte PM (1985) Role of serotonin in blood pressure regulation. In: Smith JAR, Watkins J, editors: Care of the postoperative surgical patient. Butterworth, London, pp 141–164

    Google Scholar 

  29. Pettersson A, Gradin K, Hedner T, Persson B (1985) Anti-hypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rate. Naunyn Schmiedebergs Arch Pharmacol 329: 394–397

    Google Scholar 

  30. Ball SG, Robertson JIS (1985) Is there α-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment? J Cardiovasc Pharmacol 7 [Suppl 7]: S120-S122

    Google Scholar 

  31. Hosie J, Gould S (1985) Does ketanserin have a first dose effect in hypertension. Br J Clin Pharmacol 20: 535P

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Gothenburg University and Sahlgren's University Hospital, Gothenburg, Sweden

    B. Persson

  2. Department of Pharmacology, Gothenburg University and Sahlgren's University Hospital, Gothenburg, Sweden

    A. Pettersson

  3. Department of Clinical Pharmacology, Gothenburg University and Sahlgren's University Hospital, Gothenburg, Sweden

    T. Hedner

Authors
  1. B. Persson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Pettersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Hedner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Persson, B., Pettersson, A. & Hedner, T. Pharmacokinetics of ketanserin in patients with essential hypertension. Eur J Clin Pharmacol 32, 259–265 (1987). https://doi.org/10.1007/BF00607573

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00607573

Key words

Search

Navigation